150 related articles for article (PubMed ID: 26838672)
21. Neuro-oncology biotech industry progress report.
Chakraborty S; Bodhinayake I; Chiluwal A; Langer DJ; Ruggieri R; Symons M; Boockvar JA
J Neurooncol; 2016 May; 128(1):175-182. PubMed ID: 26897014
[TBL] [Abstract][Full Text] [Related]
22. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
23. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
[TBL] [Abstract][Full Text] [Related]
25. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
26. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
27. Small-Molecule-Based Lineage Reprogramming Creates Functional Astrocytes.
Tian E; Sun G; Sun G; Chao J; Ye P; Warden C; Riggs AD; Shi Y
Cell Rep; 2016 Jul; 16(3):781-92. PubMed ID: 27396343
[TBL] [Abstract][Full Text] [Related]
28. 5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.
Zhang F; Liu Y; Zhang Z; Li J; Wan Y; Zhang L; Wang Y; Li X; Xu Y; Fu X; Zhang X; Zhang M; Zhang Z; Zhang J; Yan Q; Ye J; Wang Z; Chen CD; Lin W; Li Q
Sci Rep; 2016 Feb; 6():20882. PubMed ID: 26864347
[TBL] [Abstract][Full Text] [Related]
29. 5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma.
Zhang LY; Han CS; Li PL; Zhang XC
Jpn J Clin Oncol; 2016 May; 46(5):427-34. PubMed ID: 26851753
[TBL] [Abstract][Full Text] [Related]
30. Integrin α6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells.
Herrmann A; Lahtz C; Song J; Aftabizadeh M; Cherryholmes GA; Xin H; Adamus T; Lee H; Grunert D; Armstrong B; Chu P; Brown C; Lim M; Forman S; Yu H
Oncogene; 2020 Mar; 39(10):2156-2169. PubMed ID: 31819166
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis.
Carella A; Tejedor JR; García MG; Urdinguio RG; Bayón GF; Sierra M; López V; García-Toraño E; Santamarina-Ojeda P; Pérez RF; Bigot T; Mangas C; Corte-Torres MD; Sáenz-de-Santa-María I; Mollejo M; Meléndez B; Astudillo A; Chiara MD; Fernández AF; Fraga MF
Int J Cancer; 2020 Jan; 146(2):373-387. PubMed ID: 31211412
[TBL] [Abstract][Full Text] [Related]
32. TET (Ten-eleven translocation) family proteins: structure, biological functions and applications.
Zhang X; Zhang Y; Wang C; Wang X
Signal Transduct Target Ther; 2023 Aug; 8(1):297. PubMed ID: 37563110
[TBL] [Abstract][Full Text] [Related]
33. Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model.
Liu Z; Chao J; Wang C; Sun G; Roeth D; Liu W; Chen X; Li L; Tian E; Feng L; Davtyan H; Blurton-Jones M; Kalkum M; Shi Y
Cell Rep; 2023 Aug; 42(8):112841. PubMed ID: 37494190
[TBL] [Abstract][Full Text] [Related]
34. Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders.
Feng L; Chao J; Ye P; Luong Q; Sun G; Liu W; Cui Q; Flores S; Jackson N; Shayento ANH; Sun G; Liu Z; Hu W; Shi Y
Adv Sci (Weinh); 2023 Aug; 10(23):e2206910. PubMed ID: 37271923
[TBL] [Abstract][Full Text] [Related]
35. Targeting epigenetic regulators to overcome drug resistance in cancers.
Wang N; Ma T; Yu B
Signal Transduct Target Ther; 2023 Feb; 8(1):69. PubMed ID: 36797239
[TBL] [Abstract][Full Text] [Related]
36. Integrin subunit alpha V is a potent prognostic biomarker associated with immune infiltration in lower-grade glioma.
Tan Z; Zhang Z; Yu K; Yang H; Liang H; Lu T; Ji Y; Chen J; He W; Chen Z; Mei Y; Shen XL
Front Neurol; 2022; 13():964590. PubMed ID: 36388191
[TBL] [Abstract][Full Text] [Related]
37. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
38. The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.
Nelczyk AT; Ma L; Gupta AD; Gamage HEV; McHenry MT; Henn MA; Kadiri M; Wang Y; Krawczynska N; Bendre S; He S; Shahoei SH; Madak-Erdogan Z; Hsiao SH; Saleh T; Carpenter V; Gewirtz DA; Spinella MJ; Nelson ER
Biochim Biophys Acta Mol Basis Dis; 2022 Nov; 1868(11):166515. PubMed ID: 35932893
[TBL] [Abstract][Full Text] [Related]
39. Genetic variants in RNA m
Chen S; Cao X; Ben S; Zhu L; Gu D; Wu Y; Li S; Yu Q
Cancer Med; 2023 Jan; 12(2):1376-1388. PubMed ID: 35861369
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type
Chao J; Feng L; Ye P; Chen X; Cui Q; Sun G; Zhou T; Tian E; Li W; Hu W; Riggs AD; Matalon R; Shi Y
iScience; 2022 Jun; 25(6):104391. PubMed ID: 35637731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
